Targets › GGCX
1 program from 1 company in 4 trials: 2 Phase 4, 2 Phase 2; Gastroenterology, Genitourinary; next expected readout Dec 2026.
Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant epoxidation of vitamin K hydroquinone to vitamin K epoxide. Couples epoxidation and carboxylation in the same active site. (UniProt, P38435)
Open in Phaseline: the race on GGCX, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tanta University | Vitamin K2 (menaquinone-7) Vitamin K-dependent carboxylation of bone and vascular proteins; cofactor for gamma-carbox | GGCX | Phase 4 | Upper Gastrointestinal Bleeding (UGIB); Chronic Kidney Diseases; Non Alcoholic Steatohepatitis; Non-alcoholic Steatohepatitis | Dec 2026 |
Upper Gastrointestinal Bleeding (UGIB) (1) Chronic Kidney Diseases (1) Non Alcoholic Steatohepatitis (1) Non-alcoholic Steatohepatitis (1)
small molecule (1)
Tanta University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.